Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

170. Short-acting beta-2 agonists (SABAs) for acute asthma in children

Short-acting beta-2 agonists (SABAs) for acute asthma in children

DynaMed Plus2017

171. Short-acting beta-2 agonists (SABAs) for acute asthma in adults and adolescents

Short-acting beta-2 agonists (SABAs) for acute asthma in adults and adolescents

DynaMed Plus2017

177. Systemic corticosteroids for acute asthma in adults and adolescents

Systemic corticosteroids for acute asthma in adults and adolescents

DynaMed Plus2017

178. Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks

Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks ©Institute for Clinical and Economic Review, 2016 Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value- Based Price Benchmarks Final Report March 14, 2016 Institute for Clinical and Economic Review ©Institute for Clinical and Economic Review, 2016 Page i Final Report (...) . Public and Representative Private Insurer Coverage Policies 59 Appendix D. Previous Systematic Reviews and Technology Assessments 63 Appendix E. Ongoing Studies 64 Appendix F. Comparative Clinical Effectiveness Supplemental Information 66 Appendix G. Comparative Value Supplemental Information 70 Appendix H. Conflict of Interest Disclosures 73 ©Institute for Clinical and Economic Review, 2016 Page iv Final Report - Mepolizumab List of Acronyms Used in this Report ACQ Asthma Control Questionnaire ACT

California Technology Assessment Forum2017

179. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma 27811070 2016 11 04 2017 02 24 1399-3003 49 1 2017 Jan The European respiratory journal Eur. Respir. J. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. 1601100 10.1183/13993003.01100-2016 We present results from the first phase III trial of once-daily tiotropium add-on to inhaled corticosteroids (ICS) plus one or more controller therapies in adolescents (...) numerical improvements in peak FEV1(0-3h) response, compared with placebo (90 mL; p=0.104), and significant improvements were observed with tiotropium 2.5 µg (111 mL; p=0.046). Numerical improvements in trough FEV1 response and asthma control were observed with both tiotropium doses, compared with placebo. The safety and tolerability of tiotropium were comparable with those of placebo.Once-daily tiotropium Respimat add-on to ICS plus one or more controller therapies in adolescents with severe

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro